注射用醋酸兰瑞肽用于胃肠胰神经内分泌肿瘤的预算影响分析

Lanreotide Acetate injection for the treatment of gastroenteropancreatic neuroendocrine tumors symptoms:a budget impact analysis

目的评估将兰瑞肽用于胃肠胰神经内分泌肿瘤症状治疗纳入医保报销范围后对医保基金的影响,为相关部门决策提供一定的参考。方法构建时间范围为5年(2020—2021年)的预算影响分析模型。通过调查统计数据和文献资料、开展专家调研并结合市场销售数据,对胃肠胰神经内分泌肿瘤的流行病学数据、症状治疗路径参数和市场份额数据进行整理。药品费用信息来源于医保支付标准和药品生产企业。结果基础分析显示,若将兰瑞肽治疗胃肠胰神经内分泌肿瘤症状纳入医保报销范围,未来5年内对药品费用的影响分别为-53.38万元、-160.54万元、-375.67万元、-645.62万元和-970.79万元;医保基金总体支出的影响分别为-37.31万元、-112.21万元、-262.53万元、-451.00万元和-677.64万元,累计药品费用和医保基金支出分别节约-2205.99万元和-1540.70万元。敏感性分析显示未改变节约医保支出的基本结果。结论将兰瑞肽治疗胃肠胰神经内分泌肿瘤症状纳入医保报销范围可明显降低医保基金支出,提高患者用药可及性。

Objective To predict the impact of medical insurance fund after lanreotide acetate in the national reimbursement drug list(NRDL),which is in the treatment of gastroenteropancreatic neuroendocrine tumors(GEP-NETs)symptoms,soas to provide references for decision-making. Methods A five-year(2020 to 2024)budget impact analys is model was constructed. The epidemiological data,treatment pathway parameters,and market share data of acromegaly therapy was sorted outfrom national statistics,published literature,expert surveys,and(or)market sales data. The drug cost information was retrieved from NRDL’s payment standards or drug manufacturer. Results According to the basic analysis,from 2020 to 2024,relevant pharmacotherapy expenditures would be decreased by 0. 5338,1. 6054,3. 7567,6. 4562,and 9. 7079 million Yuan respectively if lanreotide acetate was reimbursed for GEP-NETs symptoms treatment. Accordingly,expenditures of the health insurance fund would be decreased by 0. 3731,1. 1221,2. 6253,4. 5100,and 6. 7764 million Yuan respectively. The cumulative drug cost and medical insurance fund expenditure saved-22. 0599 million yuan and-15. 4070 million yuan,respectively. Sensitivity analysis results indicated that the base-case analysis was robust. Conclusion The introduction of lanreotide acetate for GEP-NETs symptoms treatmentinto Chinese NRDL would have a cost-saving budget impact on the overall expenditure and optimize the accessibility of pharmacotherapy.